Keyword: Vasant Narasimhan
In the Netherlands, Lutathera's price is about five times that of some hospital-made products using the same radioactive ingredient.
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its next-generation cell and gene therapies.
2018 might be remembered by pharma for a deluge of consumer health castoffs. And one doesn’t really need a crystal ball to see the trend continue.
What does it take for a company to attract millennials? An inspiring culture—and jeans, according to Novartis CEO Vas Narasimhan.
The Novartis CEO said he was "completely blindsided" by news of the $1.2 million payment to Michael Cohen after just three months on the job.
Just one day after Novartis laid out plans for its Alcon spinoff, it found itself fending off a rumor that it also intends to wave goodbye to Sandoz.
Novartis once estimated a spinoff of its eye-care unit Alcon could be worth up to $35 billion, but it's facing some challenges.
Novartis has stumbled with a couple of its recent cancer launches, namely the CAR-T drug Kymriah and Ibrance rival Kisqali. But not so with Lutathera.
Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.